Literature DB >> 11884611

hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis.

Angela Iervolino1, Giorgia Santilli, Rossana Trotta, Clara Guerzoni, Vincenzo Cesi, Anna Bergamaschi, Carlo Gambacorti-Passerini, Bruno Calabretta, Danilo Perrotti.   

Abstract

hnRNP A1 is a nucleocytoplasmic shuttling heterogeneous nuclear ribonucleoprotein that accompanies eukaryotic mRNAs from the active site of transcription to that of translation. Although the importance of hnRNP A1 as a regulator of nuclear pre-mRNA and mRNA processing and export is well established, it is unknown whether this is relevant for the control of proliferation, survival, and differentiation of normal and transformed cells. We show here that hnRNP A1 levels are increased in myeloid progenitor cells expressing the p210(BCR/ABL) oncoprotein, in mononuclear cells from chronic myelogenous leukemia (CML) blast crisis patients, and during disease progression. In addition, in myeloid progenitor 32Dcl3 cells, BCR/ABL stabilizes hnRNP A1 by preventing its ubiquitin/proteasome-dependent degradation. To assess the potential role of hnRNP A1 nucleocytoplasmic shuttling activity in normal and leukemic myelopoiesis, a mutant defective in nuclear export was ectopically expressed in parental and BCR/ABL-transformed myeloid precursor 32Dcl3 cells, in normal murine marrow cells, and in mononuclear cells from a CML patient in accelerated phase. In normal cells, expression of this mutant enhanced the susceptibility to apoptosis induced by interleukin-3 deprivation, suppressed granulocytic differentiation, and induced massive cell death of granulocyte colony-stimulating factor-treated cultures. In BCR/ABL-transformed cells, its expression was associated with suppression of colony formation and reduced tumorigenic potential in vivo. Moreover, interference with hnRNP A1 shuttling activity resulted in downmodulation of C/EBPalpha, the major regulator of granulocytic differentiation, and Bcl-X(L), an important survival factor for hematopoietic cells. Together, these results suggest that the shuttling activity of hnRNP A1 is important for the nucleocytoplasmic trafficking of mRNAs that encode proteins influencing the phenotype of normal and BCR/ABL-transformed myeloid progenitors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884611      PMCID: PMC133663          DOI: 10.1128/MCB.22.7.2255-2266.2002

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  62 in total

1.  Pre-mRNA splicing imprints mRNA in the nucleus with a novel RNA-binding protein that persists in the cytoplasm.

Authors:  N Kataoka; J Yong; V N Kim; F Velazquez; R A Perkinson; F Wang; G Dreyfuss
Journal:  Mol Cell       Date:  2000-09       Impact factor: 17.970

Review 2.  Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays.

Authors:  S Ghaffari; G Q Daley; H F Lodish
Journal:  Leukemia       Date:  1999-08       Impact factor: 11.528

3.  c-myc and c-myb protein degradation: effect of metabolic inhibitors and heat shock.

Authors:  B Lüscher; R N Eisenman
Journal:  Mol Cell Biol       Date:  1988-06       Impact factor: 4.272

4.  Isolation of a recombinant copy of the gene encoding C/EBP.

Authors:  W H Landschulz; P F Johnson; E Y Adashi; B J Graves; S L McKnight
Journal:  Genes Dev       Date:  1988-07       Impact factor: 11.361

5.  Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease.

Authors:  C Gambacorti-Passerini; R Barni; E Marchesi; M Verga; F Rossi; F Rossi; P Pioltelli; E Pogliani; G M Corneo
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

6.  BCR-ABL down-regulates the DNA repair protein DNA-PKcs.

Authors:  E Deutsch; A Dugray; B AbdulKarim; E Marangoni; L Maggiorella; S Vaganay; R M'Kacher; S D Rasy; F Eschwege; W Vainchenker; A G Turhan; J Bourhis
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

7.  Heterogeneous ribonucleoprotein A1 is part of an exon-specific splice-silencing complex controlled by oncogenic signaling pathways.

Authors:  N Matter; M Marx; S Weg-Remers; H Ponta; P Herrlich; H König
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

8.  The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage.

Authors:  A H Elmaagacli; D W Beelen; B Opalka; S Seeber; U W Schaefer
Journal:  Ann Hematol       Date:  2000-08       Impact factor: 3.673

9.  BCR-ABL prevents c-jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase CbetaII-dependent pathway.

Authors:  D Perrotti; A Iervolino; V Cesi; M Cirinná; S Lombardini; E Grassilli; S Bonatti; P P Claudio; B Calabretta
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

10.  Isolation of an active gene encoding human hnRNP protein A1. Evidence for alternative splicing.

Authors:  G Biamonti; M Buvoli; M T Bassi; C Morandi; F Cobianchi; S Riva
Journal:  J Mol Biol       Date:  1989-06-05       Impact factor: 5.469

View more
  51 in total

1.  SPSB1-mediated HnRNP A1 ubiquitylation regulates alternative splicing and cell migration in EGF signaling.

Authors:  Feng Wang; Xing Fu; Peng Chen; Ping Wu; Xiaojuan Fan; Na Li; Hong Zhu; Ting-Ting Jia; Hongbin Ji; Zefeng Wang; Catherine C L Wong; Ronggui Hu; Jingyi Hui
Journal:  Cell Res       Date:  2017-01-13       Impact factor: 25.617

2.  IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1.

Authors:  Yijiang Shi; Patrick Frost; Bao Hoang; Angelica Benavides; Joseph Gera; Alan Lichtenstein
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

3.  Role of cellular RNA processing factors in human immunodeficiency virus type 1 mRNA metabolism, replication, and infectivity.

Authors:  Joseph A Jablonski; Massimo Caputi
Journal:  J Virol       Date:  2008-11-12       Impact factor: 5.103

4.  A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.

Authors:  Mario Notari; Paolo Neviani; Ramasamy Santhanam; Bradley W Blaser; Ji-Suk Chang; Annamaria Galietta; Anne E Willis; Denis C Roy; Michael A Caligiuri; Guido Marcucci; Danilo Perrotti
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

5.  Immune and inflammatory pathways are involved in inherent bone marrow ossification.

Authors:  Umut Atakan Gurkan; Ryan Golden; Vipuil Kishore; Catherine P Riley; Jiri Adamec; Ozan Akkus
Journal:  Clin Orthop Relat Res       Date:  2012-09       Impact factor: 4.176

Review 6.  Chronic myeloid leukemia: mechanisms of blastic transformation.

Authors:  Danilo Perrotti; Catriona Jamieson; John Goldman; Tomasz Skorski
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

7.  High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Authors:  Ji Suk Chang; Ramasamy Santhanam; Rossana Trotta; Paolo Neviani; Anna M Eiring; Edward Briercheck; Mattia Ronchetti; Denis C Roy; Bruno Calabretta; Michael A Caligiuri; Danilo Perrotti
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

8.  PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.

Authors:  Tasneem Motiwala; Sarmila Majumder; Kalpana Ghoshal; Huban Kutay; Jharna Datta; Satavisha Roy; David M Lucas; Samson T Jacob
Journal:  J Biol Chem       Date:  2008-11-07       Impact factor: 5.157

9.  Heterogeneous nuclear ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt signaling.

Authors:  Oak D Jo; Jheralyn Martin; Andrew Bernath; Janine Masri; Alan Lichtenstein; Joseph Gera
Journal:  J Biol Chem       Date:  2008-06-18       Impact factor: 5.157

10.  Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis.

Authors:  Morgan O'Hayre; Catherina L Salanga; Thomas J Kipps; Davorka Messmer; Pieter C Dorrestein; Tracy M Handel
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.